NCT00569699已完成2 期
Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
The purpose of this study is to determine whether S-1 and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed colorectal carcinoma with inoperable, locally advanced, or metastatic disease, not amenable to curative therapy
- •Measurable disease or non-measurable but assessable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)
- •Patients with no previous treatment (radiotherapy or chemotherapy). Patients who have received postoperative adjuvant chemotherapy are eligible if relapse is diagnosed more than 180 days after the end of such treatment.
- •Treatment with FOLFIRI and FOLFOX is not indicated.
- •Age >65 years
- •Life expectancy of at least 3 months
- •ECOG PS of 0, 1, or 2
- •Adequate function of major organs as defined below:
- •Hemoglobin >9.0 g/dL
- •White blood cell count >3,500/mm3, <12,000/mm3
- •Neutrophil count >1,500/mm3
- •Platelet count >100,000/mm3
- •Total bilirubin <1.5 mg/dL
- •AST and ALT <100 U/L (<200 U/L in patients with liver metastasis)
- •Serum creatinine <1.2 mg/dL
- •Creatinine clearance estimate by the Cockcroft-Gault method >50 mL/min
- •Able to take capsules orally.
- •No electrocardiographic abnormalities within 28 days before enrollment that would clinically preclude the execution of the study, as judged by the investigator.
- •Voluntary written informed consent.
排除标准
- •Serious drug hypersensitivity or a history of drug allergy
- •Active double cancer
- •Active infections (e.g., patients with pyrexia of 38℃ or higher)
- •Uncontrolled hypertension
- •Serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart failure, renal failure, hepatic failure, or poorly controlled diabetes)
- •Moderate or severe ascites or pleural effusion requiring treatment
- •Watery diarrhea
- •Treatment with flucytosine
- •Metastasis to the CNS
- •Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers. Men who are currently attempting to conceive children.
- •Severe mental disorder
- •Continuous treatment with steroids
- •Urine dipstick for proteinuria should be <2+
- •Thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism
- •Major surgical procedure, open biopsy, or clinically significant traumatic injury within 4 weeks
- •Long-term daily treatment with aspirin (>325 mg/day)
- •History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
- •Judged ineligible for participation in the study by the investigator for safety reasons.
研究组 & 干预措施
1
Experimental
S-1, Bevacizumab
干预措施: S-1, Bevacizumab (Drug)
结局指标
主要结局
Progression free survival
时间窗: every course for first three courses, then every other course
次要结局
- Safety, Response rate, Time to progression, Time to treatment failure, Overall survival, Treatment situation(any time)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.Colorectal CancerNCT01159171Hoffmann-La Roche50
已完成
2 期
Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLCNon-small Cell Lung CancerNCT04345146Sun Yat-sen University100
已完成
1 期
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV MelanomaMelanomaNCT00790010Dana-Farber Cancer Institute46
已完成
1 期
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma PatientsMetastatic Renal Cell CarcinomaKidney CancerNCT00421512Memorial Sloan Kettering Cancer Center28
已完成
1 期
Bevacizumab and Sunitinib in Treating Patients With Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00357318National Cancer Institute (NCI)60